Kirby Institute, UNSW, 17th April 2023 A ten-year study into the impact of HIV ‘treatment as prevention’ has found that a 27 per cent increase in people accessing effective HIV treatment saw HIV infections decrease by 66 per cent between 2010 to 2019, in NSW and Victoria. The findings, published today in Lancet HIV, show the success of HIV treatment as prevention in reducing new HIV infections...
Implementing community-based Dried Blood Spot (DBS) testing for HIV and hepatitis C
Young, J., Ablona, A., Klassen, B.J. et al. Implementing community-based Dried Blood Spot (DBS) testing for HIV and hepatitis C: a qualitative analysis of key facilitators and ongoing challenges. BMC Public Health 22, 1085 (2022). Abstract: Background In 2018, the Community-Based Research Centre (CBRC) invited gay, bisexual, trans, queer men and Two-Spirit and non-binary people (GBT2Q) at Pride...
Client-led care in HIV: perspectives from community and practice
Crawford, D, Allan, B, Cogle, A, Brown, G. Client-led care in HIV: perspectives from community and practice. HIV Med. 2021; 22 (Suppl 1): 3– 14. While current antiretroviral and care strategies can effectively suppress HIV, achieving optimal quality of life (QoL) requires a wider consideration of clients’ well-being, the complexity of individuals’ lives and social determinants of health. The...
Consensus statement on the role of health systems in advancing the long-term well-being of PLHIV
NAPWHA (National Association of people with HIV Australia), July 2021 Despite access to effective ART and viral suppression, people living with HIV often report poor well-being and health-related quality of life. A multidisciplinary panel of 44 global HIV experts articulate how health systems can advance the long-term well-being of people living with HIV by addressing multi-morbidity, health...
FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment
Poz.com, January 21, 2021 On January 21, the Food and Drug Administration (FDA) in the USA approved the first complete injectable HIV treatment regimen that does not require daily pills. Cabenuva, from ViiV Healthcare, is administered only once a month. It is approved for people with an undetectable viral load on their current therapy who wish to switch to a long-acting regimen. Cabenuva consists...
U = U: awareness and associations with health outcomes among PLHIV in 25 countries
Okoli C, Van de Velde N, Richman B, et al Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries Sexually Transmitted Infections Published Online First: 30 July 2020. doi: 10.1136/sextrans-2020-054551 Abstract: Objectives ‘Undetectable equals Untransmittable’ (U=U) is an empowering message that may enable people...